- Poster presentation
- Open Access
Urinary tract infections caused by Pseudomonas aeruginos among children in southern Poland
https://doi.org/10.1186/2047-2994-4-S1-P262
© Pobiega et al; licensee BioMed Central Ltd. 2015
- Published: 16 June 2015
Keywords
- Urinary Tract Infection
- Amikacin
- Tobramycin
- Imipenem
- Meropenem
Introduction
Urinary tract infections (UTIs) are an important cause of morbidity and mortality during the first 2 years of life. Knowledge of the antimicrobial resistance patterns may help clinicians choosing the empirical treatment.
Objectives
The aim was to analyze the resistance and virulence of PAR causing UTIs among children in Southern Poland.
Methods
PCR-screening for lasB, exoS, pilA, aprA and pilB and antimicrobial-susceptibility were performed. MDR was non-susceptible to one antimicrobial in ≥3 antimicrobial classes. Extensively-drug resistant (XDR) was susceptible to ≤2 antimicrobial classes. PCR-screening for VIM, IMP and KPC was performed.
Results
Median age (Q1;Q3) of the population (25 children) was 1.5 year (1;3). The most prevalent virulence gene was exoS (92.3%), modulating bacterial phagocytosis and invasion into cells. LasB gene (degrades of human competent molecules), was present among 80.8% of the isolates. AprA (aeruginolysin that degrades biologically important proteins) was present in 61.5%. PilB gene was not detected. Of the isolates, 92% were susceptible to gentamycin, tobramycin or cefepime, 85% to amikacin. A large number of isolates were resistant to meropenem (38.5%) or imipenem (19.2%). All were susceptible to colistin. Two isolates were XDR, 1 was MBL-positive. No KPC, IMP, VIM were found.
Conclusion
Empirical selection of the antibiotics should be based on the knowledge of local antimicrobial susceptibilities of pathogens rather than on universal guidelines to maximize the benefit for patients and minimize the risk of developing drug-resistance. In this study, gentamycin and beta-lactams were shown to be the most appropriate for UTIs empiric therapy among children. Supported by 2012/05/N/NZ7/00786
Disclosure of interest
None declared.
Authors’ Affiliations
Copyright
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
